JP2013542239A - 後眼部疾患の治療のための液体医薬組成物 - Google Patents
後眼部疾患の治療のための液体医薬組成物 Download PDFInfo
- Publication number
- JP2013542239A JP2013542239A JP2013538191A JP2013538191A JP2013542239A JP 2013542239 A JP2013542239 A JP 2013542239A JP 2013538191 A JP2013538191 A JP 2013538191A JP 2013538191 A JP2013538191 A JP 2013538191A JP 2013542239 A JP2013542239 A JP 2013542239A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- eye
- segment
- composition according
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
(表1)
−眼圧上昇の管理に有用なプロスタグランジン類似体、例えばラタノプロスト、ビマトプロスト、タフルプロスト、トラボプロストおよびウノプロストンなど;
−炎症過程の管理に有用なコルチコステロイド、例えばトリアムシノロン、デキサメタゾン、フルオロメトロン、ヒドロコルチゾン、プレドニゾロン、およびリメキソロンなど;
−抗生物質、例えばオーレオマイシン、アジスロマイシン、ゲンタマイシン、シプロフロキサシン、オフロキサシン、フシジン酸、カナマイシン、レボフロキサシン、ロメフロキサシン、オキシテトラサイクリン、トブラマイシン、ナタマイシン、ゲンタマイシン、およびモキシフロキサシンなど;
−眼内圧を低下させるために有用なβアドレナリン遮断薬、例えばカルテオロール、チモロール、メチプラノロール、ベタキソロール、ピンドロール、およびレボブノロールなど;
−緑内障の管理に有用なコリン系薬物、例えばブリモニジン、クロニジン、ジピベフリン、アプラクロニジン、カルバコール、およびピロカルピンなど;
−緑内障の管理に有用な炭酸脱水酵素阻害剤、例えばブリンゾラミドおよびドルゾラミドなど;
−眼科用投与に有用なウイルス抑止剤(virustatic agents)、例えばアシクロビル、トリフルリジン、およびガンシクロビルなど;ならびに
−非ステロイド性抗炎症薬、例えば、ジクロフェナク、ブロムフェナク、ケトロラック、フルルビプロフェン、およびインドメタシンなど
が、そのいずれの塩および溶媒和物も含めて挙げられる。
Claims (15)
- 患者の後眼部に付随する組織の治療のための医薬組成物であって、前記組成物が、少なくとも1.2g/mlの密度を有する非水性の生理学的に許容できる液体ビヒクルを含み、かつ、前記治療が、前記眼の表面への局所投与および/または眼球周囲注射を含む、医薬組成物。
- 前記治療に、前記組成物の投与の後の一定期間がさらに含まれ、その期間の間、前記患者は上方に顔を向ける仰臥位の状態であって、前記期間が、前記組成物を投与部位から前記後眼部の部位へ移動させるのに十分である、請求項1に記載の医薬組成物。
- 前記患者が、加齢性黄斑変性、糖尿病性網膜症、緑内障、網膜色素変性症、およびサイトメガロウイルス網膜炎から選択される疾患または状態に罹患している、請求項1または2に記載の医薬組成物。
- 前記液体ビヒクルが、パーフルオロカーボン、部分フッ素化アルカン、ポリシロキサン、およびそれらの混合物から選択される、請求項1〜3のいずれか一項に記載の医薬組成物。
- 液体ビヒクルが、式
RFRH
または式
RFRHRF
に従う部分フッ素化アルカンを含み、
上式で、RFは、20個以下の炭素原子をもつ過フッ素化炭化水素セグメントであり、
RHは、3〜20個の炭素原子をもつ非フッ素化炭化水素セグメントである、請求項4に記載の組成物。 - 前記部分フッ素化アルカンが、式
RFRH
の化合物であり、
上式で、RFは、3〜10個の炭素原子をもつ線状過フッ素化炭化水素セグメントであり、RHは、3〜10個の炭素原子をもつ線状アルキル基である、請求項5に記載の組成物。 - 前記部分フッ素化アルカンが、F4H5、F6H6およびF6H8から選択される、請求項5に記載の組成物。
- 前記液体ビヒクルの密度が少なくとも約1.35g/mlである、請求項1〜7のいずれか一項に記載の医薬組成物。
- 前記液体ビヒクルの沸点が少なくとも約120℃である、請求項1〜8のいずれか一項に記載の医薬組成物。
- 約5mPas以下の動的粘度を有する、請求項1〜9のいずれか一項に記載の医薬組成物。
- 前記液体ビヒクルの屈折率が、20℃で1.29〜1.35の範囲内である、請求項1〜10のいずれか一項に記載の医薬組成物。
- 溶解または分散形態の活性医薬成分を含み、その活性成分が、所望により、ラタノプロスト、ビマトプロスト、タフルプロスト、トラボプロスト、ウノプロストン、トリアムシノロン、デキサメタゾン、フルオロメトロン、ヒドロコルチゾン、プレドニゾロン、リメキソロン、オーレオマイシン、アジスロマイシン、ゲンタマイシン、シプロフロキサシン、オフロキサシン、フシジン酸、カナマイシン、レボフロキサシン、ロメフロキサシン、オキシテトラサイクリン、トブラマイシン、ナタマイシン、ゲンタマイシン、モキシフロキサシン、カルテオロール、チモロール、メチプラノロール、ベタキソロール、ピンドロール、レボブノロール、ブリモニジン、クロニジン、ジピベフリン、アプラクロニジン、カルバコール、ピロカルピン、ブリンゾラミド、ドルゾラミド、アシクロビル、トリフルリジン、ガンシクロビル、ジクロフェナク、ブロムフェナク、ケトロラック、フルルビプロフェン、およびインドメタシン、及びそれらの任意の塩もしくは溶媒和物から選択される、請求項1〜11のいずれか一項に記載の医薬組成物。
- 共溶媒、界面活性剤、安定剤、抗酸化薬、防腐剤、および着色剤から選択される1以上の賦形剤をさらに含む、請求項1〜12のいずれか一項に記載の医薬組成物。
- 少なくとも約24時間の期間にわたって活性成分の持続放出をもたらすように処方されている、請求項1〜13のいずれか一項に記載の医薬組成物。
- 患者の後眼部に付随する組織の疾患または状態を治療するための方法であって、(a)少なくとも1.2g/mlの密度を有する非水性の生理学的に許容できる液体ビヒクルを含む医薬組成物を前記眼の表面への局所投与、および/または眼球周囲注射によって投与すること、ならびにその後に(b)前記患者を、前記組成物を投与部位から前記後眼部の部位へ移動させるのに十分な長さの一定期間、上方に顔を向ける仰臥位にさせることを含む、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10190832.5 | 2010-11-11 | ||
EP10190832A EP2462921A1 (en) | 2010-11-11 | 2010-11-11 | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
PCT/EP2011/069795 WO2012062834A1 (en) | 2010-11-11 | 2011-11-10 | Liquid pharmaceutical composition for the treatment of a posterior eye disease |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016175104A Division JP6545137B2 (ja) | 2010-11-11 | 2016-09-08 | 後眼部疾患の治療のための液体医薬組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013542239A true JP2013542239A (ja) | 2013-11-21 |
JP2013542239A5 JP2013542239A5 (ja) | 2014-11-06 |
Family
ID=43616980
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013538191A Pending JP2013542239A (ja) | 2010-11-11 | 2011-11-10 | 後眼部疾患の治療のための液体医薬組成物 |
JP2016175104A Active JP6545137B2 (ja) | 2010-11-11 | 2016-09-08 | 後眼部疾患の治療のための液体医薬組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016175104A Active JP6545137B2 (ja) | 2010-11-11 | 2016-09-08 | 後眼部疾患の治療のための液体医薬組成物 |
Country Status (8)
Country | Link |
---|---|
US (2) | US9241900B2 (ja) |
EP (3) | EP2462921A1 (ja) |
JP (2) | JP2013542239A (ja) |
KR (1) | KR20140032935A (ja) |
CN (2) | CN103200931B (ja) |
AU (2) | AU2011328102B2 (ja) |
CA (1) | CA2813851C (ja) |
WO (1) | WO2012062834A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021515758A (ja) * | 2018-03-02 | 2021-06-24 | ノバリック ゲーエムベーハー | ネビボロールを含む医薬組成物 |
JP2021518352A (ja) * | 2018-03-28 | 2021-08-02 | ノバリック ゲーエムベーハー | チモロールを含む医薬組成物 |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210069016A1 (en) * | 2008-11-13 | 2021-03-11 | Gholam A. Peyman | Neurodegenerative Disorder Treatment Method |
KR101656121B1 (ko) | 2010-03-17 | 2016-09-08 | 노바리크 게엠베하 | 안압 증가를 치료하기 위한 약학 조성물 |
EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
PL2714010T3 (pl) | 2011-05-25 | 2017-08-31 | Novaliq Gmbh | Kompozycja farmaceutyczna do miejscowego stosowania oparta na semifluorowanych alkanach |
EP2714008B1 (en) | 2011-05-25 | 2016-12-14 | Novaliq GmbH | Pharmaceutical composition for administration to nails |
WO2013110621A1 (en) | 2012-01-23 | 2013-08-01 | Novaliq Gmbh | Stabilised protein compositions based on semifluorinated alkanes |
PL2708228T3 (pl) * | 2012-09-12 | 2018-11-30 | Novaliq Gmbh | Kompozycje do przemywania oczu |
JP6039152B2 (ja) * | 2012-09-12 | 2016-12-07 | ノバリック ゲーエムベーハー | 半フッ素化アルカン組成物 |
CN113679697A (zh) * | 2012-09-12 | 2021-11-23 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
US20160279055A1 (en) | 2013-07-22 | 2016-09-29 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof |
US20150164882A1 (en) | 2013-07-22 | 2015-06-18 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions for intraocular administration and methods for fabricating thereof |
KR102272568B1 (ko) * | 2013-07-23 | 2021-07-05 | 노바리크 게엠베하 | 안정화 항체 조성물 |
WO2015029948A1 (ja) * | 2013-08-26 | 2015-03-05 | リンク・ジェノミクス株式会社 | 網膜色素上皮の障害を原因とする網膜疾患の予防または治療剤 |
CN108349855B (zh) * | 2015-09-30 | 2021-07-20 | 诺瓦利克有限责任公司 | 用于眼部给药的半氟化化合物 |
DE202016008738U1 (de) | 2015-09-30 | 2019-04-09 | Novaliq Gmbh | Semifluorierte Verbindungen und ihre Zusammensetzungen |
ES2763121T3 (es) | 2016-06-23 | 2020-05-27 | Novaliq Gmbh | Método de administración tópica |
CN109922794B (zh) * | 2016-08-18 | 2022-11-04 | 特洛伊.布雷莫 | 使用脂质体构建体将尿素递送至黄斑和视网膜的细胞 |
CN116172987A (zh) | 2016-09-22 | 2023-05-30 | 诺瓦利克有限责任公司 | 用于治疗睑缘炎的药物组合物 |
US10813976B2 (en) | 2016-09-23 | 2020-10-27 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
CA3056030A1 (en) | 2017-03-10 | 2018-09-13 | Pfizer Inc. | Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors |
CN110678207A (zh) | 2017-04-21 | 2020-01-10 | 诺瓦利克有限责任公司 | 碘组合物 |
US20180318319A1 (en) | 2017-05-04 | 2018-11-08 | Ocular Science, Inc. | Compositions and Methods for Treating Eyes and Methods of Preparation |
US10717691B2 (en) | 2017-05-05 | 2020-07-21 | Novaliq Gmbh | Process for the production of semifluorinated alkanes |
US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
WO2018215638A1 (en) * | 2017-05-26 | 2018-11-29 | Novaliq Gmbh | Pharmaceutical compositions comprising azithromycin |
CN111372566A (zh) | 2017-09-27 | 2020-07-03 | 诺瓦利克有限责任公司 | 用于治疗眼部疾病的包含拉坦前列素的眼科用组合物 |
CN111182893A (zh) | 2017-10-04 | 2020-05-19 | 诺瓦利克有限责任公司 | 包含f6h8的眼用组合物 |
WO2019206956A1 (en) * | 2018-04-27 | 2019-10-31 | Novaliq Gmbh | Ophthalmic compositions comprising tafluprost for the treatment of glaucoma |
WO2020036658A2 (en) * | 2018-04-27 | 2020-02-20 | The Johns Hopkins University | Drugs promoting retinal rod photoreceptor survival |
WO2019213358A1 (en) * | 2018-05-03 | 2019-11-07 | Alimera Sciences, Inc. | Methods of treating retinal diseases |
SG11202102820VA (en) | 2018-10-12 | 2021-04-29 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
US11071724B2 (en) | 2019-05-17 | 2021-07-27 | Ocular Science, Inc. | Compositions and methods for treating presbyopia |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2616927A (en) * | 1950-05-12 | 1952-11-04 | Minnesota Mining & Mfg | Fluorocarbon tertiary amines |
JPS6452722A (en) * | 1987-05-01 | 1989-02-28 | Anjierini Pharmaceut Inc | Ophthalmic composition |
US5336175A (en) * | 1992-10-29 | 1994-08-09 | Mames Robert N | Method for the treatment of retinal detachments |
US5518731A (en) * | 1990-09-27 | 1996-05-21 | Allergan, Inc. | Nonaqueous fluorinated drug delivery vehicle suspensions |
JP2000511157A (ja) * | 1995-09-29 | 2000-08-29 | マイネルト,ハッソ | セミフルオロアルカン及びその使用 |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10022A (en) | 1853-09-13 | Lard-lamp | ||
US4452818A (en) | 1982-03-19 | 1984-06-05 | Haidt Sterling J | Extraocular method of treating the eye with liquid perfluorocarbons |
US5077036A (en) | 1986-01-14 | 1991-12-31 | Alliance Pharmaceutical Corp. | Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid |
US6458376B1 (en) | 1990-09-27 | 2002-10-01 | Allergan, Inc. | Nonaqueous fluorinated drug delivery suspensions |
US5326566A (en) | 1991-05-17 | 1994-07-05 | Bristol-Myers Squibb Company | Use of dibutyl adipate and isopropyl myristate in topical and transdermal products |
FR2679150A1 (fr) | 1991-07-17 | 1993-01-22 | Atta | Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations. |
US6602900B2 (en) | 1992-09-21 | 2003-08-05 | Allergan, Inc. | Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
DE4405627A1 (de) | 1994-02-22 | 1995-08-24 | Hoechst Ag | Fluorkohlenwasserstoffe enthaltende Ölemulsionen |
FR2720943B1 (fr) | 1994-06-09 | 1996-08-23 | Applic Transferts Technolo | Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples. |
US6294563B1 (en) * | 1994-10-27 | 2001-09-25 | Allergan Sales, Inc. | Combinations of prostaglandins and brimonidine or derivatives thereof |
US5696164A (en) | 1994-12-22 | 1997-12-09 | Johnson & Johnson Consumer Products, Inc. | Antifungal treatment of nails |
US5667809A (en) | 1995-06-07 | 1997-09-16 | Alliance Pharmaceutical Corp. | Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents |
US5874481A (en) | 1995-06-07 | 1999-02-23 | Alliance Pharmaceutical Corp. | Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents |
US5874469A (en) | 1996-01-05 | 1999-02-23 | Alcon Laboratories, Inc. | Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs |
FR2752161B1 (fr) | 1996-08-07 | 1998-09-25 | Atta | Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles |
IN184589B (ja) | 1996-10-16 | 2000-09-09 | Alza Corp | |
DE19709704C2 (de) | 1997-03-10 | 1999-11-04 | Michael Georgieff | Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie |
US5980936A (en) | 1997-08-07 | 1999-11-09 | Alliance Pharmaceutical Corp. | Multiple emulsions comprising a hydrophobic continuous phase |
US5981607A (en) | 1998-01-20 | 1999-11-09 | Allergan | Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers |
ATE238751T1 (de) | 1998-02-09 | 2003-05-15 | Macrochem Corp | Antimykotischer nagellack |
DE19861012A1 (de) | 1998-03-18 | 1999-09-30 | Pharm Pur Gmbh | Behandlungsmittel für die Ophthalmologie |
ES2211151T3 (es) | 1998-08-19 | 2004-07-01 | Skyepharma Canada Inc. | Dispersiones acuosas inyectables de propofol. |
US6140374A (en) | 1998-10-23 | 2000-10-31 | Abbott Laboratories | Propofol composition |
US6159977A (en) | 1998-11-16 | 2000-12-12 | Astan, Inc. | Therapeutic anti-fungal nail preparation |
NZ513441A (en) | 1999-02-08 | 2004-01-30 | Alza Corp | Stable non-aqueous single phase viscous drug delivery vehicles comprising a polymer a solvent and a surfactant |
US7258869B1 (en) | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
EP1124416A1 (en) | 1999-03-15 | 2001-08-22 | John Claude Krusz | Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages |
US6177477B1 (en) | 1999-03-24 | 2001-01-23 | American Home Products Corporation | Propofol formulation containing TRIS |
US6239113B1 (en) | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
DE19926890C1 (de) | 1999-06-12 | 2000-07-27 | Pharm Pur Gmbh | Verwendung eines hochfluorierten oligomeren Alkans in der Ophthalmologie |
DE19938668B4 (de) | 1999-08-14 | 2006-01-26 | Bausch & Lomb Inc. | Tränenersatzmittel |
JP2001158734A (ja) | 1999-12-02 | 2001-06-12 | Lion Corp | 眼科用組成物及びソフトコンタクトレンズに対する吸着抑制方法 |
US20030018044A1 (en) | 2000-02-18 | 2003-01-23 | Peyman Gholam A. | Treatment of ocular disease |
US6399087B1 (en) | 2000-12-20 | 2002-06-04 | Amphastar Pharmaceuticals, Inc. | Propofol formulation with enhanced microbial inhibition |
CA2446060A1 (en) | 2001-05-07 | 2002-11-14 | Corium International | Compositions and delivery systems for administration of a local anesthetic agent |
RU2302857C2 (ru) | 2001-09-04 | 2007-07-20 | Тромсдорф ГмбХ унд Ко.КГ Арцнаймиттель | Способ и пластырь для профилактики и/или лечения дисфункции и/или нарушения роста ногтей |
US7074827B2 (en) | 2002-10-24 | 2006-07-11 | Sucampo Ag (Usa) Inc. | Method for treating ocular hypertension and glaucoma |
EP2977043A3 (en) | 2003-08-25 | 2016-04-06 | Foamix Pharmaceuticals Ltd. | Penetrating pharmaceutical foam |
US20050079210A1 (en) | 2003-10-09 | 2005-04-14 | Gupta Shyam K. | Liposomal delivery system for topical pharmaceutical, cosmeceutical, and cosmetic ingredients |
PT1670433E (pt) | 2003-10-10 | 2012-02-08 | Ferring Bv | Fórmula farmacológica transdérmica para a minimização de resíduos na pele |
EP1684724A4 (en) | 2003-11-19 | 2008-04-02 | Barnes Jewish Hospital | IMPROVED DRUG DELIVERY |
GB0408164D0 (en) | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
EP1740189B1 (en) | 2004-04-19 | 2012-06-13 | Centre National De La Recherche Scientifique -Cnrs- | Lung surfactant supplements |
US20050288196A1 (en) | 2004-06-08 | 2005-12-29 | Ocularis Pharma, Inc. | Silicone polymer contact lens compositions and methods of use |
NZ552481A (en) | 2004-07-01 | 2008-12-24 | Schepens Eye Res | Compositions and methods for treating eye disorders and conditions |
US20060078580A1 (en) | 2004-10-08 | 2006-04-13 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
US7740875B2 (en) | 2004-10-08 | 2010-06-22 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
EP1688161A1 (en) | 2004-11-02 | 2006-08-09 | Switch Biotech Aktiengesellschaft | Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis |
US7851504B2 (en) | 2005-03-16 | 2010-12-14 | Allergan, Inc. | Enhanced bimatoprost ophthalmic solution |
GB0511499D0 (en) | 2005-06-06 | 2005-07-13 | Medpharm Ltd | Topical ungual formulations |
MX2008001746A (es) | 2005-08-05 | 2008-04-07 | Bharat Serums & Vaccines Ltd | Composiciones de emulsion de propofol intravenosas que tienen eficacia de conservacion. |
FR2892023B1 (fr) | 2005-10-14 | 2009-09-25 | Galderma Sa | Composition pharmaceutique a base d'amorolfine et d'agent filmogene hydrosoluble pour application ungueale et peri-ungueale |
DE102005055811A1 (de) | 2005-11-23 | 2007-05-31 | Novaliq Gmbh | Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen |
TWI376239B (en) | 2006-02-01 | 2012-11-11 | Andrew Xian Chen | Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof |
AR062046A1 (es) | 2006-07-25 | 2008-08-10 | Osmotica Pharmaceutical Argentina S A | Soluciones oftalmicas |
JP5694664B2 (ja) | 2006-09-29 | 2015-04-01 | サーモディクス,インコーポレイティド | 生分解性眼用インプラント及び眼の病気を治療する方法 |
FR2918891B1 (fr) | 2007-07-20 | 2009-09-25 | Thea Sa Lab | Solution ophtalmique a base de prostaglandines sans conservateur |
CN101347619A (zh) * | 2007-07-20 | 2009-01-21 | 天津药业研究院有限公司 | 一种药物组合物及其在制备治疗眼部炎症的药物中的应用 |
DE102007055046A1 (de) | 2007-11-19 | 2009-05-28 | Fluoron Gmbh | Infusionslösung |
PL2110126T3 (pl) | 2008-04-18 | 2012-04-30 | Novaliq Gmbh | Zastosowanie do inhalacji i zakraplania semifluorowanych alkanów jako nośników substancji aktywnych w strefie wewnątrzpłucnej |
EP2367527A2 (en) | 2008-11-26 | 2011-09-28 | SurModics, Inc. | Implantable ocular drug delivery device and methods |
US8501800B2 (en) | 2009-03-05 | 2013-08-06 | Insite Vision Incorporated | Controlled-release ophthalmic vehicles |
IT1393419B1 (it) | 2009-03-19 | 2012-04-20 | Medivis S R L | Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6. |
WO2010146536A1 (en) | 2009-06-18 | 2010-12-23 | Koninklijke Philips Electronics N.V. | Suspension of particles with drug |
US9012503B2 (en) | 2009-06-25 | 2015-04-21 | Lion Corporation | Ophthalmic composition |
JP5736635B2 (ja) | 2009-06-25 | 2015-06-17 | ライオン株式会社 | ドライアイ治療剤 |
PL2387391T3 (pl) | 2009-07-24 | 2017-09-29 | Mika Pharma Gesellschaft Für Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh | Sposób otrzymywania ciekłej kompozycji stosowalnej w postaci piany na skórę oraz kompozycja do aplikowania miejscowego |
EP2332525A1 (en) | 2009-11-23 | 2011-06-15 | Novaliq GmbH | Pharmaceutical composition comprising propofol |
EP2335735A1 (en) | 2009-12-14 | 2011-06-22 | Novaliq GmbH | Pharmaceutical composition for treatment of dry eye syndrome |
US20110223208A1 (en) | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
KR101656121B1 (ko) | 2010-03-17 | 2016-09-08 | 노바리크 게엠베하 | 안압 증가를 치료하기 위한 약학 조성물 |
DE102010022567A1 (de) | 2010-06-02 | 2011-12-08 | Fluoron Gmbh | Zubereitung |
EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
WO2012060179A1 (ja) | 2010-11-04 | 2012-05-10 | シャープ株式会社 | 符号化装置、復号装置、符号化方法、復号方法、プログラム、記録媒体、および符号化データのデータ構造 |
EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
AU2012204932B2 (en) | 2011-01-04 | 2017-02-23 | Novaliq Gmbh | O/w-emulsions comprising semifluorinated alkanes |
PL2714010T3 (pl) | 2011-05-25 | 2017-08-31 | Novaliq Gmbh | Kompozycja farmaceutyczna do miejscowego stosowania oparta na semifluorowanych alkanach |
EP2714008B1 (en) | 2011-05-25 | 2016-12-14 | Novaliq GmbH | Pharmaceutical composition for administration to nails |
WO2013110621A1 (en) | 2012-01-23 | 2013-08-01 | Novaliq Gmbh | Stabilised protein compositions based on semifluorinated alkanes |
JP6039152B2 (ja) | 2012-09-12 | 2016-12-07 | ノバリック ゲーエムベーハー | 半フッ素化アルカン組成物 |
CN113679697A (zh) | 2012-09-12 | 2021-11-23 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
EP2783703A1 (en) | 2013-03-25 | 2014-10-01 | B. Braun Melsungen AG | Semifluorocarbon compound containing contrast agent |
KR102272568B1 (ko) | 2013-07-23 | 2021-07-05 | 노바리크 게엠베하 | 안정화 항체 조성물 |
CN108349855B (zh) | 2015-09-30 | 2021-07-20 | 诺瓦利克有限责任公司 | 用于眼部给药的半氟化化合物 |
-
2010
- 2010-11-11 EP EP10190832A patent/EP2462921A1/en not_active Withdrawn
-
2011
- 2011-11-10 CN CN201180053796.1A patent/CN103200931B/zh not_active Expired - Fee Related
- 2011-11-10 CA CA2813851A patent/CA2813851C/en active Active
- 2011-11-10 EP EP11785373.9A patent/EP2637642B1/en not_active Not-in-force
- 2011-11-10 WO PCT/EP2011/069795 patent/WO2012062834A1/en active Application Filing
- 2011-11-10 AU AU2011328102A patent/AU2011328102B2/en not_active Ceased
- 2011-11-10 CN CN201610824512.9A patent/CN106924180B/zh active Active
- 2011-11-10 US US13/884,785 patent/US9241900B2/en active Active
- 2011-11-10 KR KR1020137010568A patent/KR20140032935A/ko not_active Application Discontinuation
- 2011-11-10 EP EP18202240.0A patent/EP3466408A1/en active Pending
- 2011-11-10 JP JP2013538191A patent/JP2013542239A/ja active Pending
-
2015
- 2015-12-17 US US14/973,461 patent/US10064944B2/en active Active
-
2016
- 2016-09-08 JP JP2016175104A patent/JP6545137B2/ja active Active
-
2017
- 2017-01-31 AU AU2017200608A patent/AU2017200608B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2616927A (en) * | 1950-05-12 | 1952-11-04 | Minnesota Mining & Mfg | Fluorocarbon tertiary amines |
JPS6452722A (en) * | 1987-05-01 | 1989-02-28 | Anjierini Pharmaceut Inc | Ophthalmic composition |
US5518731A (en) * | 1990-09-27 | 1996-05-21 | Allergan, Inc. | Nonaqueous fluorinated drug delivery vehicle suspensions |
US5336175A (en) * | 1992-10-29 | 1994-08-09 | Mames Robert N | Method for the treatment of retinal detachments |
JP2000511157A (ja) * | 1995-09-29 | 2000-08-29 | マイネルト,ハッソ | セミフルオロアルカン及びその使用 |
Non-Patent Citations (6)
Title |
---|
JPN6015019844; Eur. J. Ophthalmol. Vol.10 No.3, 2000, pp.189-197 * |
JPN6015019847; Graefes Arch. Clin. Exp. Ophthalmol. Vol.239, 2001, pp.373-381 * |
JPN6016016148; PRACTICE Vol.26 No.5, 2009, pp.474-476 * |
JPN6016016151; 肥満と糖尿病 Vol.4 No.2, 2005, pp.284-286 * |
JPN6016016155; あたらしい眼科 Vol.16 No.7, 1999, pp.995-998 * |
JPN7015001328; Database Registry on STN RN: 338-83-0, 1984 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021515758A (ja) * | 2018-03-02 | 2021-06-24 | ノバリック ゲーエムベーハー | ネビボロールを含む医薬組成物 |
JP7353292B2 (ja) | 2018-03-02 | 2023-09-29 | ノバリック ゲーエムベーハー | ネビボロールを含む医薬組成物 |
JP2021518352A (ja) * | 2018-03-28 | 2021-08-02 | ノバリック ゲーエムベーハー | チモロールを含む医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
US20130303473A1 (en) | 2013-11-14 |
EP3466408A1 (en) | 2019-04-10 |
CN106924180B (zh) | 2020-12-22 |
CN106924180A (zh) | 2017-07-07 |
CA2813851A1 (en) | 2012-05-18 |
KR20140032935A (ko) | 2014-03-17 |
US9241900B2 (en) | 2016-01-26 |
CN103200931A (zh) | 2013-07-10 |
EP2462921A1 (en) | 2012-06-13 |
CN103200931B (zh) | 2016-10-19 |
CA2813851C (en) | 2017-10-03 |
JP2017019842A (ja) | 2017-01-26 |
AU2011328102B2 (en) | 2016-11-03 |
AU2017200608A1 (en) | 2017-02-23 |
EP2637642A1 (en) | 2013-09-18 |
US20160101178A1 (en) | 2016-04-14 |
US10064944B2 (en) | 2018-09-04 |
AU2017200608B2 (en) | 2018-02-15 |
WO2012062834A1 (en) | 2012-05-18 |
AU2011328102A1 (en) | 2013-05-02 |
EP2637642B1 (en) | 2019-01-09 |
JP6545137B2 (ja) | 2019-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6545137B2 (ja) | 後眼部疾患の治療のための液体医薬組成物 | |
JP5816636B2 (ja) | 眼圧上昇の治療のための医薬組成物 | |
JP5770297B2 (ja) | 有効成分の送達のための液体医薬組成物 | |
JP2021518352A (ja) | チモロールを含む医薬組成物 | |
CN112153970A (zh) | 用于治疗青光眼的包含他氟前列素的眼用组合物 | |
CN111372566A (zh) | 用于治疗眼部疾病的包含拉坦前列素的眼科用组合物 | |
JP2021515758A (ja) | ネビボロールを含む医薬組成物 | |
Regnier | Barriers to Ocular Drug Delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140918 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140918 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150522 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150522 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150812 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151120 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160510 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160908 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20160915 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20161111 |